BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21890225)

  • 1. Phase I study of radiochemotherapy with gemcitabine in invasive bladder cancer.
    Borut K; Lijana ZK
    Radiother Oncol; 2012 Mar; 102(3):412-5. PubMed ID: 21890225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
    Choudhury A; Swindell R; Logue JP; Elliott PA; Livsey JE; Wise M; Symonds P; Wylie JP; Ramani V; Sangar V; Lyons J; Bottomley I; McCaul D; Clarke NW; Kiltie AE; Cowan RA
    J Clin Oncol; 2011 Feb; 29(6):733-8. PubMed ID: 21205754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial.
    De Santis M; Bachner M; Cerveny M; Kametriser G; Steininger T; Königsberg R; Schratter-Sehn A; Sedlmayer F; Dittrich C
    Ann Oncol; 2014 Sep; 25(9):1789-1794. PubMed ID: 24936582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients.
    Atasoy BM; Dane F; Alsan Cetin I; Ozgen Z; Ucuncu Kefeli A; Ibrahimov R; Turhal NS; Abacioglu U; Turkeri L
    Clin Transl Oncol; 2014 Jan; 16(1):91-5. PubMed ID: 23615982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gemcitabine in advanced bladder cancer].
    Lehmann J; Retz M; Lippert C; Albers P; Stöckle M
    Urologe A; 2003 Jan; 42(1):63-77. PubMed ID: 12574885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bladder preservation possibilities in the treatment of muscle-invasive bladder cancer].
    Asadauskiene J; Aleknavicius E; Zelviene TP; Jankevicius F
    Medicina (Kaunas); 2006; 42(10):781-7. PubMed ID: 17090976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Effective and Well Tolerated Strategy of Bladder Preservation Therapy in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.
    Feng YH; Shen KH; Huang KH; Tzeng WS; Li CF; Lin KL
    Clin Genitourin Cancer; 2016 Feb; 14(1):e67-74. PubMed ID: 26428609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxic epidermal necrolysis associated with gemcitabine therapy in a patient with metastatic transitional cell carcinoma of the bladder.
    Mermershtain W; Cohen AD; Lazarev I; Grunwald M; Ariad S
    J Chemother; 2003 Oct; 15(5):510-1. PubMed ID: 14598945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer.
    Sangar VK; McBain CA; Lyons J; Ramani VA; Logue JP; Wylie JP; Clarke NW; Cowan RA
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):420-5. PubMed ID: 15667962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials.
    Caffo O; Thompson C; De Santis M; Kragelj B; Hamstra DA; Azria D; Fellin G; Pappagallo GL; Galligioni E; Choudhury A
    Radiother Oncol; 2016 Nov; 121(2):193-198. PubMed ID: 27720221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
    Galsky MD; Hahn NM; Powles T; Hellerstedt BA; Lerner SP; Gardner TA; Yu M; O'Rourke M; Vogelzang NJ; Kocs D; McKenney SA; Melnyk AM; Hutson TE; Rauch M; Wang Y; Asmar L; Sonpavde G
    Clin Genitourin Cancer; 2013 Jun; 11(2):175-81. PubMed ID: 23228446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial.
    Kent E; Sandler H; Montie J; Lee C; Herman J; Esper P; Fardig J; Smith DC
    J Clin Oncol; 2004 Jul; 22(13):2540-5. PubMed ID: 15226322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Toxicity of intravesical gemcitabine in superficial bladder cancer treatment].
    Beardo Villar P; Gamaza Martínez R; Gavira Moreno R
    Farm Hosp; 2014 May; 38(3):249-51. PubMed ID: 24951911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
    Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
    J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial.
    Azria D; Riou O; Rebillard X; Thezenas S; Thuret R; Fenoglietto P; Pouessel D; Culine S
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):853-9. PubMed ID: 24368064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a Phase II Hoosier Oncology Group Study.
    Montie JE
    J Urol; 2005 Nov; 174(5):1784. PubMed ID: 16217286
    [No Abstract]   [Full Text] [Related]  

  • 18. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
    Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
    J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.
    Serretta V; Galuffo A; Pavone C; Allegro R; Pavone-MacAluso M
    Urology; 2005 Jan; 65(1):65-9. PubMed ID: 15667865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy concurrent with weekly gemcitabine after transurethral tumor resection in muscle ınvasive bladder cancer.
    Demirci U; Dızdar O; Cetindag MF; Altınova S; Ozsavran A; Dede DS; Kızılırmak N; Eraslan FA; Yalcın B; Cinkir HY
    J Cancer Res Ther; 2015; 11(4):704-7. PubMed ID: 26881505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.